An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer

Completed · Phase 1

Conditions studied: Metastatic Colorectal Cancer

In brief

The purpose of this study is to predict response to Erbitux as a single agent in patients with metastatic colon cancer

Key facts

Study ID

NCT00207155

Run by

Eli Lilly and Company

People needed

110

Starts

2003-12-01

Expected to finish

2006-02-01

Last updated by the study team

2015-10-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Measurable disease Tumor available for biopsies. Life expectancy of at least 3 months.

You may not qualify if…

• Known or documented brain metastases prior to Cetuximab therapy.

Where it is running

• Local Institution — Duarte, California, United States
• Local Institution — Tampa, Florida, United States
• Local Institution — Baltimore, Maryland, United States
• Local Institution — St Louis, Missouri, United States
• Local Institution — New Brunswick, New Jersey, United States
• Local Institution — The Bronx, New York, United States
• Local Institution — Cincinnati, Ohio, United States
• Local Institution — Cleveland, Ohio, United States
• Local Institution — Hershey, Pennsylvania, United States
• Local Institution — Philadelphia, Pennsylvania, United States
• Local Institution — Nashville, Tennessee, United States
• Local Institution — San Antonio, Texas, United States
• Local Institution — Montreal, Quebec, Canada
• Local Institution — Barcelona, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.